Thrombocytosis (Thrombocythemia)

03/01/2001 - "Aspirin is effective for patients with thrombocythemia, but most other cases are very resistant to treatment. "
01/01/2000 - "Low-dose aspirin will prevent the microvascular thrombotic complications of thrombocythemia associated with PV in remission after phlebotomy, but lacks myelosuppressive activity. "
06/01/1986 - "Thrombocytosis was previously present as attested by a blood count one year before (in one case) and by long-term peripheral vasomotor troubles, electively improved by aspirin (in two cases). "
12/01/2018 - "This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients with ET age 40 to 59 years and without high-risk factors or extreme thrombocytosis. "
01/01/2019 - "In conclusion, twice-daily dosing with low-dose aspirin provides a more consistent platelet inhibition compared with standard once-daily dosing in patients with essential thrombocytosis."

11/01/2021 - "Anagrelide is considered to be very effective treatment for essential thrombocytosis. "
10/01/2003 - "These patients received anagrelide for 25 months resulting in a significant improvement of thrombocytosis. "
01/01/1992 - "Our experience suggests that anagrelide should become a useful agent in controlling the thrombocythemia seen in chronic myeloproliferative diseases and can be effective in patients in whom treatment with currently available agents has failed."
01/01/1992 - "To evaluate the safety and efficacy of anagrelide when used to reduce platelet counts in patients with thrombocytosis. "
11/01/2004 - "Herein, we report the results of a long-term study of patients with ET treated with anagrelide to control thrombocytosis. "

01/01/1991 - "Recently, many authors have reported the therapeutical efficacy of interferon (IFN) in MPD with thrombocytosis in decreasing platelet number. "
01/01/1987 - "Taking advantage of this effect, we investigated the efficacy of recombinant interferon (rec-IFN) in the treatment of thrombocytosis in myeloproliferative diseases. "
09/30/1989 - "In a prospective open study 16 consecutive patients with a myeloproliferative syndrome and thrombocytosis were treated with interferon (IFN) alpha-2a. "
10/01/2020 - "Pegylated interferon can control myelodysplastic/myeloproliferative syndrome with ring sideroblasts and thrombocytosis."
11/13/1993 - "The effect of interferons in the correction of thrombocytosis in chronic myeloproliferative syndromes is well known. "

10/01/1992 - "In comparison, serum IL-6 levels of patients with reactive thrombocytosis were significantly greater than controls (38.3 U/ml +/- 94.6; range 0-933; P < 0.001). "
10/01/1991 - "In contrast, serum IL-6 levels of 143 patients (158 samples) with reactive thrombocytosis were significantly greater than controls (38.3 U/ml +/- 94.6; P less than 0.001), with 83% of the samples showing elevated serum IL-6. "
12/01/2006 - "This study showed that thrombocytosis in HSP patients is a type of inflammatory reactive thrombocytosis, and that IL-6 may also play a role in the pathogenesis of HSP."
09/01/2002 - "This study provided no direct evidence as to the mechanism responsible for the elevated platelet count, but mediation by interleukin-6 (IL-6) was concluded to be an attractive hypothesis, consistent with prior studies of IL-6 in reactive thrombocytosis and of IL-6 in ENL."
01/01/2020 - "Thrombocytosis showed significant correlation with white blood cells instead of serum IL-6, which implies that the inflammatory process may influence both parameters. "

01/01/2023 - "A woman in her 80s initially presented with numerous, primarily photodistributed, crusted, and ulcerated plaques of the trunk and extremities and a medical history of essential thrombocytosis treated with hydroxyurea for 14 years. "
01/01/2021 - "Hydroxyurea treats extreme thrombocytosis. "
01/01/2021 - "Thrombocytosis can be prothrombotic, so cytoreductive hydroxyurea is often initiated after this surgery; however, optimal dosing strategy and efficacy are unknown. "
08/01/2020 - "IAT was uniquely predictive of developing extreme thrombocytosis (ExT, platelets ≥1000 K/μL, 90% vs. 15.7%, risk ratio 4.11, P < 0.0001) despite standardized hydroxyurea use. "
04/01/2015 - "An 81-year-old Caucasian woman, affected by polycytemia vera lasting 17 years, presented in March 2012 with hyperleukocytosis, absolute neutrophilia, and thrombocytosis despite hydroxyurea treatment. "

02/01/2002 - "These results indicate that plasma thrombopoietin levels may be helpful in distinguishing between clonal and reactive thrombocytosis."
05/01/1998 - "Thrombopoietin levels may be helpful in distinguishing between clonal thrombocytosis and reactive thrombocytosis. "
01/01/2021 - "In this study, a rat model of partial LT was used, and the impact of thrombopoietin (TPO)-induced perioperative thrombocytosis on graft regeneration, IRI, and survival was investigated. "
09/01/2004 - "The aims of this study were to evaluate the prevalence and clinical significance of thrombocytosis in HCC patients and its relationships with serum thrombopoietin (TPO). "
02/01/2002 - "The aim of this study is to assess circulating thrombopoietin concentrations in patients with both clonal and reactive thrombocytosis (RT), which are two distinct categories of extreme platelet production circumstances. "

01/01/1999 - "Although it is possible that spontaneous remission (frequency 5%-10%) of chronic ITP coincided with the femoral lengthening, limb lengthening could also have caused the thrombocytosis. "
08/01/2019 - "Compared to the thrombocytosis patients, ITP patients had higher percentages of CD4 + HLA-DR+ T cells and CD8 + HLA-DR+ T cells, and lower CD4 + CD69+ T cells and CD8 + CD69+ T cells. "
08/01/2019 - "A cohort of 92 hospitalized ITP patients, 49 unrelated healthy children, and 48 thrombocytosis patients were enrolled in this retrospective study between February 2013 and September 2018. "
01/01/2016 - "We present a case report and review of the literature pertaining to this complication and provide recommendations for preventing postsplenectomy thrombocytosis in ITP patients on TPO-RAs."
01/01/1991 - "A morphometric and immunohistochemical study was performed on trephine biopsies of the bone marrow in patients showing idiopathic thrombocytopenic purpura (ITP) and reactive thrombocytosis (RTH). "

01/01/2020 - "Risk factors for thrombi comprise apical TTS, elevated levels of C-reactive protein and troponine, thrombocytosis, persisting ST segment elevation and right-ventricular involvement. "
01/01/2018 - "For CLI diabetes (p < 0.001, OR 2.44, 95% CI 1.97-3.02), hsCRP (p < 0.001, OR 1.01, 95% CI 1.01-1.01), age (p < 0.001, OR 1.05, 95% CI 1.04-1.06), thrombocytosis (p = 0.025, OR 1.84, 95%CI 1.08-3.14), and MPV (p = 0.003, OR 0.84, 95% CI 0.75-0.94) were significant independent predictors for CLI. "
01/01/2018 - "Blood sampling at that time revealed a microcytic anaemia, reactive thrombocytosis and raised inflammatory markers (erythrocyte sedimentation rate 99 mm/hour, C-reactive protein 161 mg/L). "
03/01/2013 - "All patients developed a raised C-reactive protein, whereas most developed acute liver injury, neutrophilia, and thrombocytosis. "
09/01/2012 - "In MIBC, serum C-reactive protein and thrombocytosis have been recently incorporated into basic prognostic models and demonstrated an increase in the predictive accuracy of standard pathological risk factors. "

09/01/2011 - "In preliminary findings of a Phase III trial in patients with primary, postpolycythemia-vera, or postessential-thrombocythemia myelofibrosis, administration at an initial dosage of 15 or 20 mg twice daily led to a spleen-volume response rate (≥ 35% reduction at 24 weeks) of 41.9 versus 0.7% for placebo (p < 0.0001); furthermore, 45.9% of the ruxolitinib recipients had ≥ 50% improvement in symptom score (on the modified Myelofibrosis Symptom Assessment Form version 2.0) versus 5.3% for placebo (p < 0.0001). "
09/16/2010 - "We conducted a phase 1−2 trial of INCB018424 in patients with JAK2 V617F−positive or JAK2 V617F−negative primary myelofibrosis, post–essential thrombocythemia myelofibrosis, or post–polycythemia vera myelofibrosis. "
09/30/2021 - "Ruxolitinib-induced extreme thrombocytosis in a COVID-19 patient."
01/01/2021 - "Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature."
01/01/2019 - "This observational multi-center study enrolled 20 adult patients with intermediate- or high-risk primary MF, post- polycythemia vera MF, or postessential thrombocythemia MF with hyperproliferative manifestations of the disease and WBC and/or platelet counts not controlled by ruxolitinib therapy. "

09/01/2021 - "We also aimed to validate whether thrombocytosis as a predictive biomarker identified patients with significantly reduced OS receiving a complete treatment break. "
11/01/2011 - "Whether secondary thrombocytosis is a distinguishing clinical biomarker of various diseases, and whether it is an independent predictor of short-term outcome of admitted medical patients is unknown and has never been examined. "
01/07/2010 - "These results establish that distinct genetic biomarker subsets can predict thrombocytosis class using routine phlebotomy."
01/07/2010 - "Class prediction models of thrombocytosis using genetic biomarkers."
04/01/2019 - "Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients."

05/01/2012 - "This report concerns 2 children with extreme thrombocytosis of 4100 × 10(9)/L and 1644 × 10(9)/L with partial and complete remission at 3 months and 4 years from diagnosis, with a follow-up of 4 and 17 years, respectively, with no cytoreduction therapy. "
09/01/2021 - "Those topics that obtained the highest scores as relevant unmet clinical needs were identified, including antiplatelet therapy in patients at low risk, definition of extreme thrombocytosis and its management in patients at low risk, indications of cytoreduction and targets of therapy, first-line treatment of choice in young patients (<60 years), and management of pregnancy. "
04/26/2023 - "The aims of this study were to assess the feasibility of performing LE FTT in patients with preoperative thrombocytosis, and whether antiplatelet (AP) therapy on the day of surgery (DOS) affects outcomes. "
03/15/2023 - "A total of 145 patients with SpA were included in this study, and non-thrombocytosis was identified in 76 patients while thrombocytosis was found in 69 patients, 38 out of the 69 patients received anti-TNF-α therapy. "
04/01/2013 - "Our study indicates that the presence of perioperative thrombocytosis in patients undergoing surgery should be considered as an independent prognostic factor of poor survival, and should be taken into account in regard to therapy."

12/01/2014 - "The two patients with splenectomy and resection of ⅔ of the spleen developed a transient thrombocytosis indicating impaired clearance of the spleen. "
06/01/2012 - "In this study, we evaluated reactive thrombocytosis that developed after splenectomy with or without additional organ resection. "
01/01/1957 - "[Clinical and biological study of a prolonged thrombocythemia after splenectomy]."
01/01/2023 - "While it is still unclear how splenectomies can result in thrombotic events in PKD, there does appear to be a correlation between splenectomies with resultant thrombocytosis with increased platelet adhesion."
03/01/2022 - "Conversely, BDL rats presented with thrombocytosis, which was not affected by splenectomy. "

05/01/2009 - "Thrombocytosis also occurred after post remission chemotherapies, although the degree of thrombocytosis gradually decreased. "
01/01/2020 - "Patients with thrombocytosis responded statistically significantly less to chemotherapy (overall response rate 35.3% and 41.6%, P = 0.046). "
08/01/2019 - "Therapeutic thrombocytapheresis for extreme thrombocytosis after chemotherapy in essential thrombocytosis."
08/01/2017 - "Thrombocytosis is seen in 25% of patients with testicular GCT and it is found to be associated with poorer chemotherapy response in metastatic patients. "
01/01/2012 - "In all, 46% patients experienced thrombocytosis following chemotherapy, with a median platelet count of 632 × 10(9)/l (range 457-1,385). "

10/01/2006 - "Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation."
07/01/2003 - "We describe the course of 25 patients with myelofibrosis (MF) due to agnogenic myeloid metaplasia (n=19) or essential thrombocytosis (n=6) who underwent allogeneic stem cell transplantation (SCT) at one of two Canadian centers. "
01/15/2015 - "RPs are a promising laboratory tool for evaluation of idiopathic thrombocytopenia (differentiating hypoproduction from accelerated platelet destruction), chemotherapy and after stem cell transplantation (predicting platelet recovery) and thrombocytosis (estimating platelet turnover). "
03/01/2013 - "Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation."
12/17/2009 - "From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70). "

12/01/2019 - "Thrombocytosis was noted in 6/15 cats after treatment. "
10/01/2004 - "At 3-7 days after treatment, subjects presented also with a mild tendency towards a normocytic anaemic state (p < 0.01) and a degree of lympho-thrombocytosis (p < 0.05). "
04/01/2003 - "60% cases had thrombocytosis at diagnosis in comparison to 2.3% after treatment. "
05/26/2021 - "We managed a patient who developed enoxaparin-associated thrombocytosis, which was completely resolved after treatment cessation. "
05/01/2009 - "These findings suggest that in APL patients, thrombocytosis after treatment with ATRA and or chemotherapy may be caused by increased plasma levels of both of IL-6 and TPO."